We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo ADLM 2025 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

AI-Enhanced Cell-Based Blood Tests to Improve Predictive Accuracy for Complex Transplant Outcomes

By LabMedica International staff writers
Posted on 04 Aug 2025

Managing immunosuppressive drugs in transplant patients is a delicate challenge. Insufficient medication can lead to rejection, which may be cell- or antibody-mediated, while excess immunosuppression raises the risk of infection and complications such as Epstein-Barr virus (EBV)-associated lymphoma. Current diagnostic tools provide limited insight into a patient’s immune status, relying on reactive, binary results. Clinicians often must combine various sources of clinical data to make critical decisions, making a timely and accurate diagnosis difficult. Now, the integration of artificial intelligence (AI) and machine learning (ML) capabilities with cell-based blood tests could significantly improve predictive accuracy for complex transplant outcomes.

Plexision (Pittsburgh, PA, USA) is advancing personalized transplant medicine using AI-enhanced cell-based testing. Plexision’s suite of cell-based blood tests predicts the most common rejection subtypes and post-transplant infections, all using a common platform of immune cell function. The company is further enhancing the platform’s predictive accuracy, enabling it to rank the likelihood of several outcomes such as stable graft function, T-cell-mediated and antibody-mediated rejection, and infection-related lymphoma. The platform delivers results in as little as 6 to 24 hours and transforms test results from binary outputs to ranked, patient-specific predictions, allowing for more tailored clinical decisions.


Image: The cell-based tests bring artificial intelligence to transplant outcome care (Photo courtesy of iStock)
Image: The cell-based tests bring artificial intelligence to transplant outcome care (Photo courtesy of iStock)

The platform has demonstrated strong clinical performance in multi-center studies. For instance, PlexABMR, one of the company’s tests, predicted antibody-mediated rejection in kidney transplant recipients with 81% positive predictive value and 75% negative predictive value. Another test accurately predicted EBV infection, a leading cause of life-threatening post-transplant lymphoma. Moving forward, Plexision aims to continue advancing its AI-driven capabilities and expand its impact in precision transplant care by delivering timely, individualized insights to clinicians managing high-risk transplant patients.

“Plexision is redefining transplant diagnostics by predicting rejection subtypes and infection risks using blood tests derived from a single immune cell function platform,” said Dr. Rakesh Sindhi, a transplant surgeon, Co-founder and Chief Scientific Officer, Plexision. "By expanding our artificial intelligence and machine learning capabilities, we are transforming how clinicians will interpret immunologic signals, moving from singular binary ‘yes/no’ answers to ranked predictions tailored to each patient.”

Related Links:
Plexision


New
Gold Member
Serological Pipets
INTEGRA Serological Pipets
POC Helicobacter Pylori Test Kit
Hepy Urease Test
New
Automated Chemiluminescence Immunoassay Analyzer
MS-i3080
New
Clinical Chemistry System
P780

Latest Molecular Diagnostics News

Non-Invasive Blood Test for Endometriosis Could Replace Surgical Procedures
04 Aug 2025  |   Molecular Diagnostics

AI-Powered Cytology Tool Detects Early Signs of Oral Cancer
04 Aug 2025  |   Molecular Diagnostics

Non-Invasive Liquid-Based Cytology Test Enables Early Endometrial Cancer Detection
04 Aug 2025  |   Molecular Diagnostics